30902 Federal Register / Vol. 61, No. 118 / Tuesday, June 18, 1996 / Notices

Other Requirements

1. Paperwork Reduction Act

Projects that involve the collection of

information from 10 or more individuals

and funded by cooperative agreement

will be subject to review by the Office

of Management and Budget (OMB)

under the Paperwork Reduction Act.

2. Human Subjects

This program involves research on

human subjects. Therefore, all

applicants must comply with the

Department of Health and Human

Services Regulations, 45 CFR Part 46,

regarding the protection of human

subjects. Assurance must be provided to

demonstrate that the project or activity

will be subject to initial and continuing

review by an appropriate institutional

review committee. The applicant will be

responsible for providing assurance in

accordance with the appropriate

guidelines and form provided in the

application kit.

In addition to other applicable

committees, Indian Health Service (IHS)

institutional review committees also

must review the project if any

component of IHS will be involved with

or support the research. If any American

Indian community is involved, its tribal

government must also approve that

portion of the project applicable to it.

3. HIV/AIDS Requirements

Recipients must comply with the

document entitled Content of AIDSRelated Written Materials, Pictorials,

Audiovisuals, Questionnaires, Survey

Instruments, and Educational Sessions

(June 1992) (a copy is in the application

kit). To meet the requirements for a

program review panel, recipients are

encouraged to use an existing program

review panel, such as the one created by

the State health department’s HIV/AIDS

prevention program. If the recipient

forms its own program review panel, at

least one member must be an employee

(or a designated representative) of a

State or local health department. The

names of the review panel members

must be listed on the Assurance of

Compliance form CDC 0.1113, which is

also included in the application kit. The

recipient must submit the program

review panel’s report that indicates all

materials have been reviewed and

approved.

4. Patient Care

Applicants should provide assurance

that all HIV-infected patients enrolled in

their studies will be linked to an

appropriate local HIV care system that

can address their specific needs such as

medical care, counseling, social

services, and therapy. Details of the HIV

care system should be provided,

describing how patients will be linked

to the system. Funds will not be made

available to support the provision of

direct care for study participants.

5. Women, Racial and Ethnic Minorities

It is the policy of the CDC to ensure

that individuals of both sexes and the

various racial and ethnic groups will be

included in CDC-supported research

projects involving human subjects,

whenever feasible and appropriate.

Racial and ethnic groups are those

defined in OMB Directive No. 15 and

include American Indian, Alaskan

Native, Asian, Pacific Islander, Black

and Hispanic. Applicants shall ensure

that women, racial and ethnic minority

populations are appropriately

represented in applications for research

involving human subjects. Where clear

and compelling rationale exist that

inclusion is inappropriate or not

feasible, this situation must be

explained as part of the application.

This policy does not apply to research

studies when the investigator cannot

control the race, ethnicity and/or sex of

subjects. Further guidance to this policy

is contained in the Federal Register,

Vol. 60, No. 179, Friday, September 15,

1995, pages 47947–47951 (a copy is

included in the application kit).

Application Submission and Deadline

The original and five copies of the

completed application packet PHS 398

(Revised 5/95, OMB No. 0925–0001)

must be submitted to Van Malone,

Grants Management Officer (ATTN:

Kevin Moore), Grants Management

Branch, Procurement and Grants Office

(625), Centers for Disease Control and

Prevention (CDC), 255 East Paces Ferry

Road, NE., Room 320, Mail Stop E–15,

Atlanta, Georgia 30305, on or before

August 2, 1996. States and local

governments may use Form PHS–5161–

1 (Revised 7/92, OMB No. 0937–0189);

however, Form PHS–398 is preferred. If

using Form PHS–5161–1, submit an

original and two copies to the address

stated above.

1. Deadline

Applications shall be considered as

meeting the deadline if they are either:

a. Received on or before the stated

deadline date; or

b. Sent on or before the deadline date

and received in time for submission to

the independent review group.

(Applicants must request a legibly dated

U.S. Postal Service postmark or obtain

a legibly dated receipt from a

commercial carrier or U.S. Postal

Service. Private metered postmarks shall

not be accepted as proof of timely

mailing.)

2. Late Applications

Applications that do not meet the

criteria in 1.a. or 1.b. above are

considered late applications. Late

applications will not be considered in

the current competition and will be

returned to the applicant.

Where to Obtain Additional

Information

A complete program description,

information on application procedures,

an application package, and business

management technical assistance may

be obtained from Kevin Moore, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE., Room 320, Mail

Stop E–15, Atlanta, Georgia 30305,

telephone (404) 842–6550, E-mail

address kgm1@opspgo1.em.cdc.gov. The

announcement will be available on one

of two Internet sites on the publication

date: CDC’s home page at http://

www.cdc.gov, or at the Government

Printing Office home page (including

free access to the Federal Register) at

http://www.access.gpo.gov.

Programmatic technical assistance

may be obtained from Jeff Efird,

Division of HIV/AIDS Prevention,

National Center for HIV, STD, TB

Prevention, Centers for Disease Control

and Prevention (CDC), 1600 Clifton

Road, NE., Mail Stop E–45, Atlanta,

Georgia 30333, telephone (404) 639–

6130. Eligible applicants are encouraged

to call before developing and submitting

their application. Please refer to

Announcement Number 625 when

requesting information.

Potential applicants may obtain a

copy of ‘‘Healthy People 2000’’ (Full

Report, Stock No. 017–001–00474–0) or

‘‘Healthy People 2000’’ (Summary

report, Stock No. 017–001–00473–1)

referenced in the Introduction from the

Superintendent of Documents,

Government Printing Office,

Washington, DC 20402–9325, telephone

(202) 512–1800.

Dated: June 11, 1996.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–15379 Filed 6–17–96; 8:45 am]

BILLING CODE 4163–18–P
Federal Register / Vol. 61, No. 118 / Tuesday, June 18, 1996 / Notices 30903

[Announcement Number 620]

Prevention of the Complications of

Hemophilia through Hemophilia

Treatment Centers

Introduction

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 1996

funds for a cooperative agreement

program to prevent the complications of

congenital bleeding disorders,

particularly hemophilia A and B

(henceforth referred to as hemophilia).

The CDC is committed to achieving

the health promotion and disease

prevention objectives of Healthy People

2000, a national activity to reduce

morbidity and mortality and improve

the quality of life. This announcement

is related to the priority area of Diabetes

and Chronic Disabling Conditions. (For

ordering a copy of Healthy People 2000,

see the Section Where to Obtain

Additional Information.)

Authority

This program is authorized under

Sections 301(a) and 317(k)(2) of the

Public Health Service Act, as amended

[42 U.S.C. 241(a) and 247b(k)(2)].

Applicable program regulations are

found in 42 CFR Part 51b—Project

Grants for Preventive Health Services.

Smoke-Free Workplace

CDC strongly encourages all grant

recipients to provide a smoke-free

workplace and to promote nonuse of all

tobacco products, and Public-Law 103–

227, the Pro-Children Act of 1994,

prohibits smoking in certain facilities

that receive Federal funds in which

education, library, day care, health care,

and early childhood development

services are provided to children.

Eligible Applicants

Assistance will be provided only to

comprehensive hemophilia treatment

centers (HTCs), defined as public or

private entities that provide: 1) regional

services to support hemophilia

comprehensive treatment centers or 2)

diagnostic and treatment services to

persons with hemophilia and other

congenital blood disorders. This

definition of HTCs is currently used by

the Health Resources and Services

Administration (HRSA) to fund a grant

program for comprehensive hemophilia

treatment centers for the provision of

prevention and care services to persons

with hemophilia and other congenital

bleeding disorders. The definition is

also used by HRSA to determine

eligibility of HTCs to receive Public

Health Pricing under the Veterans

Health Care Act.

Because of the degree of

specialization required in the treatment

of hemophilia, competition is limited to

HTCs as defined above.

This project requires experience in

providing comprehensive outreach,

diagnostic, treatment, and preventive

services to patients with hemophilia

which can only be provided by HTCs.

One award per region will be made to

support the core HTC and other

contracting or collaborating HTCs in the

region. For the purposes of these

awards, regional breakdowns are as

follows: Region I: Connecticut, Maine,

Massachusetts, New Hampshire, Rhode

Island, and Vermont; Region II: New

Jersey, New York, Puerto Rico, and the

U.S. Virgin Islands; Region III:

Delaware, the District of Columbia,

Maryland, Pennsylvania, Virginia, and

West Virginia; Region IV-North:

Kentucky, North Carolina, South

Carolina, and Tennessee; Region IVSouth: Alabama, Florida, Georgia, and

Mississippi; Region V-East: Indiana,

Michigan, and Ohio; Region V-West:

Illinois, Minnesota, North Dakota, South

Dakota, and Wisconsin; Region VI:

Arkansas, Louisiana, Oklahoma, and

Texas; Region VII: Iowa, Kansas,

Missouri, and Nebraska; Region VIII:

Arizona, Colorado, Montana, New

Mexico, Utah, and Wyoming; Region IX:

California, Hawaii, Nevada, American

Samoa, Northern Mariana Islands and

Guam; Region X: Alaska, Idaho, Oregon,

and Washington.

Availability of Funds

Approximately $5,700,000 is available

in FY 1996 to fund approximately 12

awards. It is expected that the awards

will range from $200,000 to $750,000.

One award will be made for each of the

following Regions: I, II, III, VI, VII, VIII,

IX, and X; two awards will be made for

each Region IV and V. It is expected that

the awards will begin on or about

September 30, 1996, and will be made

for a 12-month budget period within a

project period of up to 5 years. Funding

estimates may vary and are subject to

change. Continuation awards within the

project period will be made on the basis

of satisfactory programmatic progress

and the availability of funds.

Purpose

The purpose of the hemophilia

complications prevention cooperative

agreement program is to assist recipients

in (1) providing comprehensive

prevention services to persons with

hemophilia or related disorders to

prevent the complications of their

bleeding disorder, (2) developing a

prevention evaluation network to assess

the efficacy of these prevention services

and make refinements as necessary, and

(3) building their capacity to serve as

public health prevention centers in the

hemophilia community.

Program Requirements

In conducting activities to achieve the

purpose of this program, the recipient

will be responsible for the activities

under A. below, and CDC will be

responsible for conducting activities

under B. below:

A. Recipient Activities

1. Implement and evaluate prevention

interventions directed at attaining

specific outcomes of reduced

complications.

a. Implement mechanisms for clinical

outcomes evaluation including

evaluation of prevention strategies.

b. Work collaboratively with specified

sites to collect standardized clinical

outcomes data.

c. Develop appropriate management

and evaluation systems to ensure that

other HTCs within the region

implement the activities of this program

appropriately and use clinical outcomes

data collection instruments.

d. Analyze, present, and publish

local, State, or regional hemophilia

prevention outcomes.

e. Develop and maintain strict

policies on protecting the

confidentiality of persons with

hemophilia, and ensure the security of

databases and other records through

controlled access to areas with

confidential information, database

password protection, locking file

cabinets, and other security features.

f. Recipients are encouraged to

propose and conduct longitudinal

clinical prevention studies of persons

with hemophilia-related complications.

2. Prioritize targets for interventions,

including, but not limited to, prevention

of joint disease in persons with

hemophilia and prevention of infections

due to unsafe blood and blood products

or unsafe practices related to treatment

of persons with hemophilia.

3. Implement intervention strategies

for reducing complications of

hemophilia.

a. Implement prevention guidelines as

they are developed and as appropriate

for providing proper prevention services

to persons with hemophilia. Develop

mechanisms for appropriate delivery of

prevention protocols, messages, and

materials to persons with hemophilia

and their family members (consumers of

hemophilia care and prevention

services, or consumers).
30904 Federal Register / Vol. 61, No. 118 / Tuesday, June 18, 1996 / Notices

b. Make available appropriate training

resources and opportunities, including

attending local, regional, or national

trainings as necessary.

c. Provide persons with hemophilia

and their family members with

appropriate and up-to-date prevention

messages and notice of training

opportunities. Prevention messages

include those directed at preventing

transmission of HIV from infected

persons with hemophilia to their sexual

partners, offspring, or other contacts, as

well as preventing other complications

of hemophilia such as joint disease and

viral diseases.

(1) Utilize these consumers as

possible in delivering prevention

messages through mechanisms of peerled prevention education, outreach, and

support.

(2) Review home infusion, home

safety, and infection control practices

with each patient and/or family as

applicable at least yearly at

comprehensive clinic visit or every

other year for patients on biennial

comprehensive visit schedules.

d. Establish mechanism for consumer

input and involvement in planning,

implementing, and assessing HTC

prevention activities. Work

collaboratively and regularly with local

hemophilia consumer organization or ad

hoc consumer consultation committee

to solicit this input.

e. Work collaboratively with other

HTCs in the region to effectively

disseminate information to HTC

personnel and clients.

4. Advise CDC of any patients who

have become newly infected with HIV

or hepatitis A, B, or C viruses (HAV,

HBV, or HCV), potentially as a result of

contaminated clotting factor

concentrates.

a. Collect sera and/or cells from

patients with hemophilia and ship these

to a central, specified laboratory for

testing and reporting results. This

central laboratory will be determined

through a contract with CDC.

5. Serve as liaison with all HTCs in

the defined region, their clients, the

Hemophilia Program at the Maternal

and Child Health Bureau, and CDC. As

a liaison be responsible for coordination

of activities of the region, including

contracting or collaborating HTCs.

Those responsibilities should include:

a. Coordinate prevention and

programmatic activities of HTCs in

region and promote collaboration of

HTCs within the region;

b. Promote collaboration of HTCs with

their local consumer organization or ad

hoc consumer consultation committee;

c. Coordinate technical assistance to

HTCs, including conducting program

assessments, site visits, and necessary

implementation of findings. Coordinate

CDC consultation when necessary;

d. Coordinate assessments of training

needs of HTC personnel and clients and

work with CDC and designated training

center as necessary to assist HTC

personnel and clients in locating

appropriate resources to meet defined

training needs. These designated

training centers will be determined by

contract with CDC.

e. Coordinate development of HTC

program plans, goals and objectives, and

progress tracking and reporting for

HTCs in the region; and

f. Coordinate, annually or bi-annually,

and with CDC participation, a regional

meeting for HTCs and consumer

organizations or ad hoc consumer

consultation committees in the region

for the purposes of information sharing

and program planning. Regional

meetings may be joint with other

regions with similar needs.

B. CDC Activities

1. Assist in setting priority areas for

prevention of complications of

hemophilia as a collaborative effort with

the participating HTCs. Provide

consultation, scientific and technical

assistance in planning, implementing,

and evaluating activities to prevent the

complications of hemophilia. This

assistance includes the development of

standard instruments to evaluate

prevention protocols and accompanying

software.

2. Assist hemophilia programs in the

implementation of prevention

guidelines developed through a

collaborative effort.

3. Provide programmatic coordination

of prevention protocol development,

including evaluation of the effectiveness

of prevention protocols and other

studies to determine the efficacy of the

guidelines.

4. Assist in the analysis and reporting

of aggregate clinical outcomes data

collected from funded programs;

coordinate and consolidate the transfer

of tabulated data, analyses, and

conclusions among recipients.

5. Provide or locate necessary followup and technical assistance to

implement any noted changes or

recommendations resulting from

programmatic evaluations or

assessments.

6. Collaborate with HTCs and

appropriate State or local health

departments to investigate any suspect

HIV, HAV, HBV, HCV or parvovirus

seroconversions that are reported by

HTCs.

7. Provide technical assistance to

coordinate routine annual testing of

patient samples for HAV, HBV, HCV,

and parvovirus and reporting of results

back to HTC. Provide technical

assistance to designated laboratory for

permanent storage of blood samples.

These laboratories will be determined

by contract with CDC.

8. Collaborate with the National

Hemophilia Foundation and other

consumer organizations to provide

appropriate mechanisms of consumer

involvement in program activities as

required in Recipient Activity number

3.

9. Participate in regional meetings of

HTCs and consumer organizations.

10. Collaborate with Regional

Coordinators, HTC personnel,

consumers, and designated training

centers to provide appropriate training

resources to providers and consumers.

11. Disseminate current information

related to the development,

implementation, and evaluation of these

regional programs to the funded HTCs

and the public as necessary and as

requested.

Evaluation Criteria

All applications will be reviewed and

evaluated according to the following

criteria: (Total 100 points).

A. Capacity (30 Points Maximum)

1. The capacity of the applicant to

access persons with hemophilia in the

region to provide prevention services.

The applicant must demonstrate the

ability to work cooperatively with all

HTCs in the region when the funds are

awarded. This is regardless of whether

other HTCs in the defined region submit

an application to be the coordinating

HTC for the region. The capacity to

access the hemophilia community is

measured by (a) the extent that this

proposal incorporates shared

responsibility between participating

HTCs to serve the patients in the

defined catchment area, and (b) the

extent to which this collaboration is

evidenced by included letters of support

from contracting or voluntary

collaborating HTCs. (15 points)

2. The scope and magnitude of

previous experiences in treatment of

hemophilia, in prevention of disease

complications, in hemophilia-related

epidemiologic or clinical studies, and in

management and coordination of a

regional network of HTCs. (7 points)

3. The allocation of time, number, and

qualifications of proposed staff to meet

stated objectives and goals; and, the

availability of facilities to be used

during the project period. (8 points)
Federal Register / Vol. 61, No. 118 / Tuesday, June 18, 1996 / Notices 30905

B. Goals and Objectives (15 Points

Maximum)

The extent to which the applicant’s

proposed goals and objectives meet the

required activities specified under ‘‘A.

Recipient Activities,’’ part 1. Required

activities for all recipients in the

Program Requirements section of this

announcement, and are measurable,

specific, time-phased, and realistic. (15

points)

C. Methods and Activities (50 Points

Maximum)

1. The quality of the applicant’s plan

for conducting program activities and

the extent to which prevention methods

proposed are: (a) Appropriate to

accomplish stated goals and objectives,

and (b) feasible within programmatic

and fiscal restrictions. (14 points)

2. The extent to which the proposal

incorporates gathering and using input

from persons with hemophilia, their

family members, and local consumer

organizations; and the applicant’s

willingness to cooperate with

consumers in the development and

implementation of prevention services.

(18 points)

3. The applicant’s willingness to

cooperate with CDC and other funded

applicants to (a) collect a unified set of

clinical outcomes data, as defined by

CDC, to assess the efficacy of prevention

activities, and (b) develop and

implement prevention protocols and

guidelines. (18 points)

D. Program Management and

Evaluation (5 Points Maximum)

The extent to which management

systems, including the types, frequency,

and methods of evaluation, are used to

assure appropriate implementation of

the activities of this program, including

implementation of program activities in

contracting and voluntary collaborating

HTCs; and, assurance that women,

racial and ethnic minority populations

are appropriately represented in

applications for research involving

human subjects. (5 points)

E. Budget

The extent to which the budget is

reasonable and consistent with the

intended use of the cooperative

agreement funds. (not scored)

F. Human Subjects

Whether or not exempt from the

DHHS regulations, are procedures

adequate for the protection of human

subjects? Recommendations on the

adequacy of protections include: (a)

Protections appear adequate and there

are no comments to make or concerns to

raise, or (b) protections appear adequate,

but there are comments regarding the

protocol, or (c) protections appear

inadequate and the Objective Review

Group has concerns related to human

subjects; or (d) disapproval of the

application is recommended because

the research risks are sufficiently

serious and protection against the risks

are inadequate as to make the entire

application unacceptable. (Not scored)

Funding Preference

In order to maximize the utility of a

service provision infrastructure, one

award will be made per region (two

awards for Regions IV and V) and

funding preference will take into

consideration geographic location.

Executive Order 12372 Review

Applications are subject to

Intergovernmental Review of Federal

Programs as governed by Executive

Order 12372. E.O. 12372 sets up a

system for State and local government

review of proposed Federal assistance

applications. Applicants should contact

their State Single Point of Contacts

(SPOCs) as early as possible to alert

them to the prospective applications

and receive any necessary instructions

on the State process. For proposed

projects serving more than one State, the

applicant is advised to contact the SPOC

for each affected State. A current list of

SPOCs is included in the application

kit. If SPOCs have any State process

recommendations on applications

submitted to CDC, they should reference

this announcement number (620) and

forward recommendations to Sharron

Orum, Grants Management Officer,

Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention

(CDC), 255 East Paces Ferry Road, NE.,

Room 300, Mailstop E–18, Atlanta,

Georgia 30305. The due date for State

process recommendations is 30 days

after the application deadline date for

new awards (the appropriation for these

awards was received late in the fiscal

year and would not allow for an

application receipt date which would

accommodate the 60 day State

recommendation process within FY

1996). CDC does not guarantee to

‘‘accommodate or explain’’ State process

recommendations it receives after that

date.

Public Health System Reporting

Requirements

This program is subject to the Public

Health System Reporting Requirements.

Under these requirements, all

community-based nongovernmental

applicants must prepare and submit the

items identified below to the head of the

appropriate State and/or local health

agency(s) in the program area(s) that

may be impacted by the proposed

project no later than the receipt date of

the Federal application. The appropriate

State and/or local health agency is

determined by the applicant. The

following information must be

provided:

a. A copy of the face page of the

application (SF 424)

b. A summary of the project that

should be titled ‘‘Public Health System

Impact Statement’’ (PHSIS), not to

exceed one page, and include the

following:

(1) A description of the population to

be served;

(2) A summary of the services to be

provided;

(3) A description of the coordination

plans with the appropriate State and/or

local health agencies.

If the State and/or local health official

should desire a copy of the entire

application, it may be obtained from the

State Single Point of Contact (SPOC) or

directly from the applicant.

Catalog of Federal Domestic Assistance

Number

The Catalog of Federal Domestic

Assistance number is 93.283, Centers for

Disease Control and Prevention (CDC)—

Investigations and Technical Assistance.

Other Requirements

Paperwork Reduction Act

Projects that involve collection of

information from 10 or more individuals

and funded by cooperative agreements

will be subject to review by the Office

of Management and Budget (OMB)

under the Paperwork Reduction Act.

Human Subjects Requirement

If the proposed project involves

research on human subjects, the

applicant must comply with the

Department of Health and Human

Services Regulations (45 CFR Part 46)

regarding the protection of human

subjects. Assurance must be provided

which demonstrate that the project will

be subject to initial and continuing

review by an appropriate institutional

review committee. The applicant will be

responsible for providing evidence of

this assurance in accordance with the

appropriate guidelines and forms

provided in the application kit.

All information obtained in

connection with this program shall not,

without such individual’s consent, be

disclosed except as may be necessary to

provide services to him or her or as may

be required by a law of a State or

political subdivision of a State.

Information derived from any such
30906 Federal Register / Vol. 61, No. 118 / Tuesday, June 18, 1996 / Notices

program may be disclosed: (1) In

summary, statistical, or other form, or

(2) for clinical or research proposed, but

only if the identity of the individuals

under such program is not disclosed.

HIV/AIDS Requirements

Recipients must comply with the

document entitled ‘‘Content of AIDSRelated Written Materials, Pictorials,

Audiovisuals, Questionnaires, Survey

Instruments, and Educational Sessions’’

(June 15, 1992), a copy of which is

included in the application kit. In

complying with the requirements for a

program review panel, recipients are

encouraged to use an existing program

review panel such as the one created by

the State health department’s HIV/AIDS

prevention program. If the recipient

forms its own program review panel, at

least one member must be an employee

(or a designated representative) of a

government health department

consistent with the content guidelines.

The names of the review panel members

must be listed on the Assurance of

Compliance form CDC 0.1113, which is

also included in the application kit. The

recipient must submit the program

review panel’s report that indicates all

materials have been reviewed and

approved, this includes conference

agendas.

Women, Racial and Ethnic Minorities

It is the policy of the Centers for

Disease Control and Prevention (CDC)

and the Agency for Toxic Substances

and Disease Registry (ATSDR) to ensure

that individuals of both sexes and the

various racial and ethnic groups will be

included in CDC/ATSDR-supported

research projects involving human

subjects, whenever feasible and

appropriate. Racial and ethnic groups

are those defined in OMB Directive No.

15 and include American Indian,

Alaskan Native, Asian, Pacific Islander,

Black and Hispanic. Applicants shall

ensure that women, racial and ethnic

minority populations are appropriately

represented in applications for research

involving human subjects. Where clear

and compelling rationale exist that

inclusion is inappropriate or not

feasible, this situation must be

explained as part of the application.

This policy does not apply to research

studies when the investigator cannot

control the race, ethnicity and/or sex of

subjects. Further guidance to this policy

is contained in the Federal Register,

Vol. 60, No. 179, pages 47947–47951,

dated Friday, September 15, 1995.

Application Submission and Deadline

The original and two copies of the

application PHS Form 5161–1 (OMB

number 0937–0189) must be submitted

to Sharron Orum, Grants Management

Officer, Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention

(CDC), 255 East Paces Ferry Road, NE.,

Room 300, Mailstop E–18, Atlanta,

Georgia 30305, on or before August 5,

1996.

1. Deadline: Applications shall be

considered as meeting the deadline if

they are either:

a. Received on or before the deadline

date; or

b. Sent on or before the deadline date

and received in time for submission to

the objective review group. (Applicants

must request a legibly dated U.S. Postal

Service postmark or obtain a legibly

dated receipt from a commercial carrier

or U.S. Postal Service. Private metered

postmarks shall not be acceptable as

proof of timely mailing.)

2. Late Applications: Applications

which do not meet the criteria in 1.a. or

1.b. above are considered late

applications. Late applications will not

be considered in the current

competition and will be returned to the

applicant.

Where to Obtain Additional

Information

A complete program description and

information on application procedures

are contained in the application

package.

Business management technical

assistance may be obtained from Locke

Thompson, Grants Management

Specialist, Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention

(CDC), 255 East Paces Ferry Road, NE.,

Room 300, Mailstop E–18, Atlanta,

Georgia 30305, (404) 842–6595; or by

Internet or CDC WONDER electronic

mail at: lxt1@opspgo1.em.cdc.gov.

Programmatic technical assistance may

be obtained from Sarah Wiley, MPH,

Hematologic Diseases Branch, Division

of AIDS, STD, and TB Laboratory

Research, National Center for Infectious

Diseases, Centers for Disease Control

and Prevention (CDC), 1600 Clifton

Road, NE., Mailstop E–64, Atlanta,

Georgia 30333, telephone (404) 639–

4026; or by Internet or CDC WONDER

electronic mail at:

sed5@ciddas1.em.cdc.gov.

Please refer to Announcement

Number 620 when requesting

information and submitting an

application.

Potential applicants may obtain a

copy of Healthy People 2000 (Full

Report, Stock No. 017–001–00474–0) or

Healthy People 2000 (Summary Report,

Stock No. 017–001–00473–1) referenced

in the Introduction through the

Superintendent of Documents,

Government Printing Office,

Washington, DC 20402–9325, telephone

(202) 512–1800.

There may be delays in mail delivery

and difficulty in reaching the CDC

Atlanta offices during the 1996 Summer

Olympics. Therefore, CDC suggests

using Internet, following all instructions

in this announcement and leaving

messages on the contact person’s voice

mail for more timely responses to any

questions.

Dated: June 11, 1996.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–15381 Filed 6–17–96; 8:45 am]

BILLING CODE 4163–18–P

[Announcement 630]

Formative Behavioral Intervention

Research on the Prevention of Sexual

Transmission of HIV by HIVSeropositive Men

Introduction

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 1996

funds for a cooperative agreement

program for the prevention of the sexual

transmission of HIV by men who have

tested positive for HIV infection.

CDC is committed to achieving the

health promotion and disease

prevention objectives of ‘‘Healthy

People 2000,’’ a national activity to

reduce morbidity and mortality and

improve the quality of life. This

announcement is related to the priority

area of Human Immunodeficiency Virus

(HIV) Infection. (For ordering a copy of

‘‘Healthy People 2000,’’ see the section

‘‘Where to Obtain Additional

Information.’’)

Authority

This program is authorized under

Sections 301 and 317(k)(2), of the Public

Health Service Act (42 U.S.C. 241 and

247b(k)(2)) as amended.

Smoke-Free Workplace

CDC strongly encourages all

recipients to provide a smoke-free

workplace and to promote the nonuse of

all tobacco products, and Public Law

103–227, the Pro-Children Act of 1994,

prohibits smoking in certain facilities

that receive Federal funds in which

education, library, day care, health care,

and early childhood development

services are provided to children.